Clinical trials: Corneal Injuries
Corneal Epithelial Disorders
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02929823
- Testing
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Where
- 19 sites in United States
- Volunteers
- 130 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Persistent Epithelial Defect
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.
- Trial name
- NCT00821561
- Testing
- Nexagon®, Nexagon® vehicle
- Volunteers
- 90 people
- Sponsor
- OcuNexus Therapeutics, Inc.
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
- Trial name
- NCT06563414
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Krystal Biotech, Inc.
Corneal Epithelial Disorders
Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02104388
- Testing
- SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution
- Where
- 17 sites in United States
- Volunteers
- 69 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to…
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Trial name
- IOLITE (NCT07016750)
- Testing
- KB803
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Krystal Biotech, Inc.
Corneal Epithelial Wound
Safety and Effectiveness of OBG vs.a Bandage Contact Lens for Large Corneal Epithelial Defects in Patients Post-PRK.
This is a prospective, randomized (Reading Center), masked, controlled study in up to 45 subjects who have undergone bilateral PRK with epithelial removal using alcohol in a 9.0 mm well or trephine at the time of surgery to…
- Trial name
- NCT03163641
- Testing
- Acuvue Oasys, Ocular Bandage Gel
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Corneal Disease, Corneal Opacity
First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness
Prospective, open label, single arm, First in Human (FIH) clinical study to assess safety and efficacy of the CorNeat Keratoprosthesis, a synthetic cornea, for the treatment of corneal blindness
- Conditions
- Corneal Disease, Corneal Opacity, Corneal Injuries
- Trial name
- NCT04485858
- Testing
- CorNeat KPro
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 10 people
- Sponsor
- CorNeat Vision Ltd.
Corneal Disease, Corneal Opacity
Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness
A Single Arm, Pivotal, Open Label, Multicenter Clinical Investigation to Evaluate the Clinical Safety and Performance of the CorNeat Keratoprosthesis, for Treatment of Corneal Blindness
- Conditions
- Corneal Disease, Corneal Opacity, Corneal Injuries
- Trial name
- NCT05694247
- Testing
- CorNeat KPro
- Where
- 6 sites in Canada, France and 2 more
- Volunteers
- 15 people
- Sponsor
- CorNeat Vision Ltd.
Corneal Epithelial Wound Healing
Cross-linked CMC and Silk Proteins in Corneal Re-epithelization
Data analyses and revision of the corneal re-epithelization in patients who underwent either PRK (Photorefractive Keratectomy), CXL (Corneal Cross-Linking), PTK (phototherapeutic keratectomy), or experienced a corneal abrasion.
- Trial name
- CLCS (NCT06840990)
- Testing
- CXC-SP, CTRL
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- D&V FARMA srl
Corneal Scar
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days.
- Trial name
- NCT06257355
- Testing
- CSB-001 Ophthalmic Solution 0.1%
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Claris Biotherapeutics, Inc.
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Diabetes
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
As a consequence of damage to multiple organ systems throughout the course of their disease, diabetic patients suffer a number of chronic complications giving rise to increased morbidity, mortality, and health care costs specific…
- Trial name
- NCT00598871
- Testing
- Thymosin Beta 4 (Tβ4)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- ReGenTree, LLC
Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes
CDL Validation Study
Ocular surface photography is significantly limited in standardization and reproducibility. This reduces its applicability for clinical monitoring of acute or chronic disease.
- Conditions
- Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes, Limbal Stem-cell Deficiency, Eye Lesion
- Trial name
- NCT05461469
- Where
- Austria
- Volunteers
- 104 people
- Sponsor
- Occyo GmbH
Ocular Trauma
Corneal Trauma Diagnostic Study
Tear fluid will be collected from patients diagnosed with ocular trauma at the University of Pittsburgh Medical Center to evaluate biomarkers.
- Trial name
- NCT07887425
- Testing
- Tear fluid collection with mass spec analysis.
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- InnSight Technology, Inc.
Cataract Extraction
Effect on Wound Healing of Vigamox Versus Cravit
The purpose of this study was to compare the effects of Vigamox and Cravit on corneal wound healing after cataract surgery.
- Trial name
- NCT00840580
- Testing
- Moxifloxacin 0.5% ophthalmic solution (Vigamox), Levofloxacin 0.5% ophthalmic solution (Cravit)
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Alcon Research
Cataracts
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.
- Trial name
- NCT01298973
- Testing
- Viscoat, Saline
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Innovative Medical
Healthy Volunteers
Study of the Safety of USB005 in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of USB005 (aclerastide) Ophthalmic Solution.
- Trial name
- NCT03615196
- Testing
- USB005 (aclerastide) Ophthalmic Solution
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- US Biotest, Inc.